系统性红斑狼疮全因与病因特异性死亡率:一项基于人群的研究
结果显示SLE患者全因死亡风险持续升高(HR 1.85,95%CI 1.66-2.06),肾脏病、感染和心血管病死亡风险显著增加,癌症死亡风险未显著增加,两个时段间无统计学显著改善。
要点
- SLE患者全因死亡风险为一般人群的1.85倍(95%CI 1.66-2.06)。
- 肾脏病、感染和心血管病死亡风险显著升高,癌症死亡风险未显著增加。
- 1997-2005与2006-14两个时段间死亡率无统计学显著改善。
核心结论
- 基于人群的研究表明SLE患者较一般人群存在持续的全因和病因特异性死亡差距。
研究设计与样本
- 利用加拿大不列颠哥伦比亚省行政健康数据库,将全部新发SLE患者按性别、年龄和索引日期与10名非SLE个体匹配。
- 队列按诊断年份分为早期队列(1997-2005)和晚期队列(2006-14)。
- 使用单变量和多变量Cox模型估计风险比(HR)和95%CI。
主要发现
- SLE患者中发生451例死亡,非SLE个体中发生1910例死亡。
- 总体SLE队列 fully adjusted 全因死亡HR为1.85(95%CI 1.66-2.06)。
- 早期与晚期队列全因死亡HR分别为1.95(95%CI 1.69-2.26)和1.74(95%CI 1.49-2.04),无统计学显著改善。
- 总体SLE队列肾脏病死亡HR为3.04(95%CI 2.29-4.05),感染死亡HR为2.74(95%CI 2.19-3.43),心血管病死亡HR为2.05(95%CI 1.77-2.38),癌症死亡HR为1.18(95%CI 0.96-1.46)。
- 早期与晚期队列病因特异性死亡率无统计学显著改善:肾脏病HR 3.57(95%CI 2.37-5.36)vs 2.65(95%CI 1.78-3.93),感染HR 2.94(95%CI 2.17-3.98)vs 2.54(95%CI 1.84-3.51),心血管病HR 1.95(95%CI 1.60-2.38)vs 2.18(95%CI 1.76-2.71)。
临床怎么用
- SLE患者全因死亡风险持续高于一般人群,应加强长期随访和共病管理。
- 肾脏病、感染和心血管病是SLE患者超额死亡的主要病因,临床需重点防控。
- 尽管两个时段间死亡率无统计学显著改善,仍应持续优化SLE综合管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate all-cause and cause-specific mortality in SLE patients between two time periods, 1997-2005 and 2006-14. METHODS: We used an administrative health database from the province of British Columbia, Canada to match all incident SLE patients to 10 non-SLE individuals on sex, age and index date. Cohorts were divided into two subgroups, according to diagnosis year: early cohort 1997-2005 and late cohort 2006-14. The outcome was death [all-cause, renal disease, cancer, infection, cardiovascular disease (CVD) and other]. Hazard ratios (HR) and 95% CIs were estimated using univariate and multivariable Cox models. RESULTS: Among 6092 SLE patients and 60 920 non-SLE individuals, there were 451 and 1910 deaths, respectively. The fully adjusted all-cause mortality HR (95% CI) in the overall SLE cohort was 1.85 (1.66, 2.06), with no statistically significant improvement between early and late cohorts [1.95 (1.69, 2.26) vs 1.74 (1.49, 2.04)]. There was excess mortality from renal disease [3.04 (2.29, 4.05)], infections [2.74 (2.19, 3.43)] and CVD [2.05 (1.77, 2.38)], but not cancer [1.18 (0.96, 1.46)], in the overall SLE cohort. There was no statistically significant improvement in cause-specific mortality between early and late cohorts for renal disease [3.57 (2.37, 5.36) vs 2.65 (1.78, 3.93)], infection [2.94 (2.17, 3.98) vs 2.54 (1.84, 3.51)] and CVD [1.95 (1.60, 2.38) vs 2.18 (1.76, 2.71)]. There was no increase in cancer-related mortality in either cohort [1.27 (0.96, 1.69) vs 1.10 (0.82, 1.48)]. CONCLUSION: This population-based study demonstrates a persisting mortality gap in all-cause and cause-specific deaths in SLE patients, compared with the general population.
引用
- Moghaddam B, Marozoff S, Li L, et al. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology (Oxford). 2021. PMID: 33871600. doi:10.1093/rheumatology/keab362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。